Sun Pharma Aisling doxorubicin injection recalled for glass particles in vials
What this means
Sun Pharmaceutical is recalling one batch of Aisling doxorubicin hydrochloride liposome injection (a cancer medication) because glass particles were found in some vials during manufacturing. Glass particles in injectable medications can cause local tissue damage, blood vessel blockage, or blood clots if injected into the bloodstream. No patient injuries have been reported so far.
- If you are a hospital, pharmacy, or healthcare provider: stop using batch HAG2581B (expiration 05/31/2027) and return it or discard it safely.
- If you have received this medication or used it: contact your doctor or healthcare provider immediately.
- Report any problems or side effects to the FDA's MedWatch program at www.fda.gov/medwatch/report.htm or call 1-800-332-1088.
- For recall questions, contact the recall processor Inmar Inc. at 855-745-9357 (Monday–Friday, 8:30 a.m.–5:00 p.m. ET) or rxrecalls@inmar.com.
Product photos
The agency's original wording
FOR IMMEDIATE RELEASE MUMBAI, INDIA and PRINCETON, NJ - May 13, 2026 – Sun Pharma is voluntarily recalling within the U.S. to the hospital/user level, one batch of DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL, Lot # HAG2581B, Expiration 05/2027 (675 vials). The single batch of 675 vials i
Official notice
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sun-pharmaceutical-industries-inc-sun-pharma-initiates-voluntary-us-nationwide-recall-doxorubicinWant us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.